Novo Nordisk seeks to block compounded Victoza

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded.

In a Citizen Petition posted on Regulations.gov, Novo Nordisk (NVO) noted